VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | The safety and efficacy of avapritinib in patients with advanced systemic mastocytosis

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares some insights into the safety and efficacy of avapritinib in patients with advanced systemic mastocytosis, and further highlights results from the PATHFINDER (NCT03580655) and EXPLORER (NCT02561988) trials. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Advisory Board and Honoraria: Novartis, Consultant and Honoraria: Blueprint Medicines, Cogent Biosciences.
Study response adjudication committees : EXPLORER/PATHFINDER – Blueprint Medicines and APEX -Cogent Biosciences.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter